• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

蒽环类药物与DNA相互作用中涉及的分子结构效应。

Molecular structural effects involved in the interaction of anthracyclines with DNA.

作者信息

Zunino F, Di Marco A, Zaccara A

出版信息

Chem Biol Interact. 1979 Feb;24(2):217-25. doi: 10.1016/0009-2797(79)90010-3.

DOI:10.1016/0009-2797(79)90010-3
PMID:428012
Abstract

Changes in DNA binding ability of daunomycin following structural modifications in the aglycone moiety have been studied by the fluorescence quenching method and by thermal denaturation of the complex. Removal of the methoxyl group at position 4 leads to a slightly stronger binding. Changes in the position of the glycosidic linkage result in a markedly weaker binding. Removal of the hydroxyl group at position 9, with the concomitant formation of a 9,10-anhydro derivative, decreases the binding ability. Methylation of hydroxyl groups at C-6 and C-11 leads to an inactive derivative and makes the binding affinity disappear almost completely. Structure-activity correlations for the DNA binding reaction deduced from these studies are in agreement with earlier findings that relate to the biological activity and confirm the general picture of the binding mechanism.

摘要

通过荧光猝灭法和复合物的热变性研究了柔红霉素糖苷配基部分结构修饰后其DNA结合能力的变化。4位甲氧基的去除导致结合略有增强。糖苷键位置的改变导致结合明显减弱。9位羟基的去除伴随着9,10-脱水衍生物的形成,降低了结合能力。C-6和C-11位羟基的甲基化产生一种无活性衍生物,使结合亲和力几乎完全消失。从这些研究中推导的DNA结合反应的构效关系与早期关于生物活性的研究结果一致,并证实了结合机制的总体情况。

相似文献

1
Molecular structural effects involved in the interaction of anthracyclines with DNA.蒽环类药物与DNA相互作用中涉及的分子结构效应。
Chem Biol Interact. 1979 Feb;24(2):217-25. doi: 10.1016/0009-2797(79)90010-3.
2
Binding of daunomycin to diaminopurine- and/or inosine-substituted DNA.柔红霉素与二氨基嘌呤和/或肌苷取代的DNA的结合。
Biochemistry. 1998 Jan 27;37(4):1033-45. doi: 10.1021/bi9716128.
3
Release of the cyano moiety in the crystal structure of N-cyanomethyl-N-(2-methoxyethyl)-daunomycin complexed with d(CGATCG).与d(CGATCG)复合的N-氰基甲基-N-(2-甲氧基乙基)柔红霉素晶体结构中氰基部分的释放
Eur J Biochem. 2000 Jan;267(2):457-64. doi: 10.1046/j.1432-1327.2000.01017.x.
4
Daunomycin binding to deoxypolynucleotides with alternating sequences: complete thermodynamic profiles of heterogeneous binding sites.柔红霉素与具有交替序列的脱氧多核苷酸的结合:异质结合位点的完整热力学概况。
Nucleosides Nucleotides Nucleic Acids. 2002 Oct;21(10):637-49. doi: 10.1081/NCN-120015722.
5
Synthesis and binding properties of conjugates between oligodeoxynucleotides and daunorubicin derivatives.寡脱氧核苷酸与柔红霉素衍生物共轭物的合成及结合特性
Nucleic Acids Res. 1997 Jun 1;25(11):2121-8. doi: 10.1093/nar/25.11.2121.
6
Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains.蒽环类抗肿瘤抗生素及相关糖侧链的酶促和化学足迹分析。
Biochemistry. 1996 Jun 18;35(24):7974-82. doi: 10.1021/bi952495o.
7
Substitutions at C2' of daunosamine in the anticancer drug daunorubicin alter its DNA-binding sequence specificity.抗癌药物柔红霉素中柔红糖胺C2'位的取代改变了其DNA结合序列特异性。
Eur J Biochem. 1996 Sep 1;240(2):331-5. doi: 10.1111/j.1432-1033.1996.0331h.x.
8
Sequence selective binding of ditrisarubicin B to DNA: comparison with daunomycin.
FEBS Lett. 1989 Jul 3;250(2):323-7. doi: 10.1016/0014-5793(89)80747-1.
9
Stereochemical requirements in the antitumor anthracyclines.抗肿瘤蒽环类药物的立体化学要求。
J Antibiot (Tokyo). 1977 Sep;30(9):764-6. doi: 10.7164/antibiotics.30.764.
10
The effects of daunomycin antibiotic on histone H(1): thermal denaturation and fluorescence spectroscopy studies.柔红霉素抗生素对组蛋白H(1)的影响:热变性和荧光光谱研究。
Int J Biol Macromol. 2000 Oct 10;28(1):75-9. doi: 10.1016/s0141-8130(00)00146-x.

引用本文的文献

1
Inhibitors of human immunodeficiency virus integrase.人类免疫缺陷病毒整合酶抑制剂。
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2399-403. doi: 10.1073/pnas.90.6.2399.
2
Intracellular pH and the control of multidrug resistance.细胞内pH值与多药耐药性的控制
Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1128-32. doi: 10.1073/pnas.91.3.1128.
3
Intravesical idarubicin--a phase-I study.
Urol Res. 1994;22(2):99-104. doi: 10.1007/BF00310999.
4
Cell biological mechanisms of multidrug resistance in tumors.肿瘤多药耐药的细胞生物学机制
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):3497-504. doi: 10.1073/pnas.91.9.3497.
5
Synthesis and antitumor activity of a platinum (II)-doxorubicin complex.
Cancer Chemother Pharmacol. 1986;18(2):180-2. doi: 10.1007/BF00262293.
6
Biochemical and biological activity of the anthracycline analog, 4-demethyl-6-O-methyl-doxorubicin.蒽环类类似物4-去甲基-6-O-甲基多柔比星的生化及生物学活性
Invest New Drugs. 1986;4(1):17-23. doi: 10.1007/BF00172011.
7
Effect of adriamycin on heart mitochondrial DNA.阿霉素对心脏线粒体DNA的影响。
Biochem J. 1987 Jul 1;245(1):309-12. doi: 10.1042/bj2450309.
8
Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.蒽环类抗肿瘤药物。物理化学、分析及稳定性性质综述。
Pharm Weekbl Sci. 1986 Apr 25;8(2):109-33. doi: 10.1007/BF02086146.
9
Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.伊达比星。对其药效学和药代动力学特性以及在癌症化疗中的治疗潜力的综述。
Drugs. 1991 Oct;42(4):690-719. doi: 10.2165/00003495-199142040-00010.